Report Phase 2 clinical trial data for Emraclidine
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Dec 2023
- Due
- 31 Dec 2024
- Delivered
- November 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Two randomized, placebo-controlled Phase 2 trials ongoing that have the potential to support approval in schizophrenia (data expected in 2H24)”
What we found
Evidence strength A What the grades mean
AbbVie reported the Phase 2 clinical trial data for Emraclidine in November 2024, which was within the expected timeframe of the second half of 2024.
-
A AbbVie Inc. 10-K filed 2025-02-14
“In November 2024, AbbVie announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia... did not meet their primary endpoint” ✓ confirmed on the page
Market reaction: the shares moved +1.5% against the S&P 500 over the three sessions around the disclosure (13 Feb 2025 to 19 Feb 2025). What this measures
Checked 5 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Emraclidine Phase 2 clinical trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you AbbVie Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ABBV-004805 · Corrections policy